Christina Rossi Sells 2,274 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.14, for a total value of $250,458.36. Following the completion of the sale, the chief operating officer now owns 67,109 shares of the company’s stock, valued at approximately $7,391,385.26. This trade represents a 3.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Christina Rossi also recently made the following trade(s):

• On Wednesday, December 18th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.91, for a total transaction of $218,099.34.
• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.10, for a total value of $216,257.40.

Blueprint Medicines Stock Performance

Shares of NASDAQ BPMC opened at $114.91 on Friday. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The company has a market capitalization of $7.30 billion, a P/E ratio of -54.46 and a beta of 0.61. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90. The stock has a 50 day moving average of $95.80 and a 200-day moving average of $95.47.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. The firm had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company’s revenue for the quarter was up 126.5% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.20) earnings per share. As a group, equities research analysts predict that Blueprint Medicines Co. will post -3.67 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $124.00 price target (down previously from $135.00) on shares of Blueprint Medicines in a report on Monday, January 13th. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Stephens reaffirmed an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. JMP Securities reissued a “market outperform” rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Wednesday, January 15th. Finally, UBS Group started coverage on Blueprint Medicines in a research note on Thursday, October 24th. They set a “neutral” rating and a $88.00 price objective for the company. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Blueprint Medicines presently has an average rating of “Moderate Buy” and an average price target of $122.72.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Hsbc Holdings PLC acquired a new position in shares of Blueprint Medicines in the second quarter valued at approximately $1,060,000. Empirical Asset Management LLC acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth $2,348,000. Massachusetts Financial Services Co. MA grew its stake in shares of Blueprint Medicines by 48.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock valued at $23,332,000 after acquiring an additional 82,693 shares in the last quarter. Entropy Technologies LP bought a new position in Blueprint Medicines during the third quarter worth about $999,000. Finally, Algert Global LLC raised its stake in Blueprint Medicines by 40.7% in the 3rd quarter. Algert Global LLC now owns 92,236 shares of the biotechnology company’s stock worth $8,532,000 after purchasing an additional 26,696 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.